Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Vascular versus myocardial dysfunction in acute coronary syndrome: are the adhesion molecules as powerful as NT-proBNP for long-term risk stratification?

Kavsak PA, Ko DT, Newman AM, Lustig V, Palomaki GE, MacRae AR, Jaffe AS.

Clin Biochem. 2008 Apr;41(6):436-9. doi: 10.1016/j.clinbiochem.2007.12.010.

2.
3.

Is a pattern of increasing biomarker concentrations important for long-term risk stratification in acute coronary syndrome patients presenting early after the onset of symptoms?

Kavsak PA, Newman AM, Ko DT, Palomaki GE, Lustig V, MacRae AR, Jaffe AS.

Clin Chem. 2008 Apr;54(4):747-51. doi: 10.1373/clinchem.2007.094664.

4.

N-terminal B-type natriuretic peptide assessment provides incremental prognostic information in patients with acute coronary syndromes and normal troponin T values upon admission.

Weber M, Bazzino O, Navarro Estrada JL, Fuselli JJ, Botto F, Perez de Arenaza D, Möllmann H, Nef HN, Elsässer A, Hamm CW.

J Am Coll Cardiol. 2008 Mar 25;51(12):1188-95. doi: 10.1016/j.jacc.2007.11.054.

5.

Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial.

Wallentin L, Lindholm D, Siegbahn A, Wernroth L, Becker RC, Cannon CP, Cornel JH, Himmelmann A, Giannitsis E, Harrington RA, Held C, Husted S, Katus HA, Mahaffey KW, Steg PG, Storey RF, James SK; PLATO study group..

Circulation. 2014 Jan 21;129(3):293-303. doi: 10.1161/CIRCULATIONAHA.113.004420.

6.

N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes.

Heeschen C, Hamm CW, Mitrovic V, Lantelme NH, White HD; Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators..

Circulation. 2004 Nov 16;110(20):3206-12.

7.

N-terminal pro-B-type natriuretic peptide complements the GRACE risk score in predicting early and late mortality following acute coronary syndrome.

Khan SQ, Narayan H, Ng KH, Dhillon OS, Kelly D, Quinn P, Squire IB, Davies JE, Ng LL.

Clin Sci (Lond). 2009 Jun 2;117(1):31-9. doi: 10.1042/CS20080419.

PMID:
19170658
8.

Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure.

de Antonio M, Lupon J, Galan A, Vila J, Urrutia A, Bayes-Genis A.

Am Heart J. 2012 May;163(5):821-8. doi: 10.1016/j.ahj.2012.03.004.

PMID:
22607860
9.

The value of N-terminal proB-type natriuretic peptide for early identification of myocardial infarction in patients with high-risk non-ST-elevation acute coronary syndromes.

Riezebos RK, Laarman GJ, Tijssen JG, Verheugt FW.

Clin Chem Lab Med. 2011 Aug;49(8):1359-65. doi: 10.1515/CCLM.2011.213.

PMID:
21692686
10.
11.

Additive prognostic value of NT-proBNP over TIMI risk score in intermediate-risk patients with acute coronary syndrome.

Eren NK, Ertaş F, Yüksek U, Cakir C, Nazli C, Köseoğlu M, Ergene O.

Turk Kardiyol Dern Ars. 2009 Jan;37(1):1-8.

12.

Dynamic changes in N-terminal pro-brain natriuretic peptide in acute coronary syndromes treated with percutaneous coronary intervention: a marker of ischemic burden, reperfusion and outcome.

Buchner S, Debl K, Barlage S, Griese D, Fredersdorf S, Jeron A, Lubnow M, Müller T, Muders F, Holmer S, Riegger GA, Luchner A.

Clin Chem Lab Med. 2010 Jun;48(6):875-81. doi: 10.1515/CCLM.2010.164.

PMID:
20441480
14.

A multimarker risk stratification approach to non-ST elevation acute coronary syndrome: implications of troponin T, CRP, NT pro-BNP and fibrin D-dimer levels.

Tello-Montoliu A, Marín F, Roldán V, Mainar L, López MT, Sogorb F, Vicente V, Lip GY.

J Intern Med. 2007 Dec;262(6):651-8.

15.

High-sensitivity cardiac troponin T: risk stratification tool in patients with symptoms of chest discomfort.

Mingels AM, Joosen IA, Versteylen MO, Laufer EM, Winkens MH, Wildberger JE, Van Dieijen-Visser MP, Hofstra L.

PLoS One. 2012;7(4):e35059. doi: 10.1371/journal.pone.0035059.

16.

Prognostic value of N-terminal pro-brain natriuretic peptide in elderly people with acute myocardial infarction: prospective observational study.

Lorgis L, Zeller M, Dentan G, Sicard P, Buffet P, L'Huillier I, Beer JC, Vincent-Martin M, Makki H, Gambert P, Cottin Y; RICO Survey Working Group..

BMJ. 2009 May 6;338:b1605. doi: 10.1136/bmj.b1605.

17.

[Is it practical to use measurement of BNP and NT-proBNP levels in patients with acute coronary syndromes?].

Przewłocki T, Gackowski A.

Kardiol Pol. 2009 Nov;67(11):1207-9. Polish. No abstract available.

18.

A combination of increased Rho kinase activity and N-terminal pro-B-type natriuretic peptide predicts worse cardiovascular outcome in patients with acute coronary syndrome.

Dong M, Liao JK, Yan B, Li R, Zhang M, Yu CM.

Int J Cardiol. 2013 Sep 10;167(6):2813-9. doi: 10.1016/j.ijcard.2012.07.007.

19.

N-terminal pro B-type natriuretic peptide in the early evaluation of suspected acute myocardial infarction.

Haaf P, Balmelli C, Reichlin T, Twerenbold R, Reiter M, Meissner J, Schaub N, Stelzig C, Freese M, Paniz P, Meune C, Drexler B, Freidank H, Winkler K, Hochholzer W, Mueller C.

Am J Med. 2011 Aug;124(8):731-9. doi: 10.1016/j.amjmed.2011.02.035.

PMID:
21787902
20.

Prognostic value of biomarkers during and after non-ST-segment elevation acute coronary syndrome.

Eggers KM, Lagerqvist B, Venge P, Wallentin L, Lindahl B.

J Am Coll Cardiol. 2009 Jul 21;54(4):357-64. doi: 10.1016/j.jacc.2009.03.056.

Supplemental Content

Support Center